Posted in | News | Medical Robotics

First Robotic-Assisted System for PCI Receives FDA Clearance

Corindus Vascular Robotics recently declared that its CorPath 200 System has achieved FDA 510(k) clearance for effective use in percutaneous coronary interventions (PCI).

The technology has gained approval in the U.S. Interventional cardiologists can now precisely perform PCI. This PCI procedure will be conducted for those affected with coronary artery disease (CAD) for blood flow restoration in their blocked arteries.

Catheterization and Cardiovascular Intervention journal featured the latest data, which illustrated that an interventional cardiologist is exposed to occupational health risks such as cataracts, orthopedic problems, and cancer when subjected to continuous exposure to radiation and the inherent physical stresses existing in the cath lab. Hence, a single-arm, multi-center study called “CorPath PRECISE Trial” functions as a platform supporting the assent of a pre-market clearance (510(k)) application to the FDA. It highlighted the safety and practical feature of robotically-assisted PCI. PCI procedure was successfully conducted in around 98.8 % of patients without any device-related complexities, eliminating the need for conversion to manual PCI. The success rate was 97.6% for overall procedure. The trial ensured the safe implementation of robotic-assisted PCI procedure. The CorPath 200 System-based PCI procedure   showed 95% reduction in radiation exposure.

The CorPath 200 System is a unique robotic-assisted procedure. In this procedure, coronary guidewires and stent or balloon catheters are precisely controlled from an optimized interventional cockpit. The lead-lined cockpit offers safety to the interventional cardiologist against harmful radiation exposure. By sitting in a position facing the monitors, surgeons can clearly visualize the angiography screen with comfort and ease.

Source: http://www.corindus.com/

Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Kaur, Kalwinder. (2019, February 20). First Robotic-Assisted System for PCI Receives FDA Clearance. AZoRobotics. Retrieved on April 18, 2024 from https://www.azorobotics.com/News.aspx?newsID=3045.

  • MLA

    Kaur, Kalwinder. "First Robotic-Assisted System for PCI Receives FDA Clearance". AZoRobotics. 18 April 2024. <https://www.azorobotics.com/News.aspx?newsID=3045>.

  • Chicago

    Kaur, Kalwinder. "First Robotic-Assisted System for PCI Receives FDA Clearance". AZoRobotics. https://www.azorobotics.com/News.aspx?newsID=3045. (accessed April 18, 2024).

  • Harvard

    Kaur, Kalwinder. 2019. First Robotic-Assisted System for PCI Receives FDA Clearance. AZoRobotics, viewed 18 April 2024, https://www.azorobotics.com/News.aspx?newsID=3045.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.